TQA3334 + nucleoside acid analogs

TQA3334 + nucleoside acid analogs is a combination therapy comprising **TQA3334**, a selective oral **toll-like receptor 7 agonist** in development for chronic hepatitis B, and **nucleoside/nucleotide acid analogs** (NAs), standard antivirals for chronic HBV infection that inhibit viral polymerase. TQA3334 is designed to modulate the host immune response through TLR7 agonism, leading to increased interferon-stimulated gene expression and antiviral activity, while nucleoside analogs suppress viral replication by targeting viral DNA polymerase. The combination aims for additive or synergistic effects, improving rates of functional cure in HBV. TQA3334 is absorbed orally and has shown dose-dependent pharmacodynamic activity in early trials. Nucleoside acid analogs commonly include drugs such as entecavir, tenofovir, and lamivudine, which are also administered orally. The primary indication for this combination is **chronic hepatitis B infection**, with ongoing clinical trials assessing its efficacy and safety[1][3][5].

Other names

TQ-A3334 + nucleoside acid analogsTQA3334 + NAs